Ian O'Reilly

Vice President Of Quality at Tessera Therapeutics

Ian O'Reilly has extensive work experience in the field of quality assurance and quality control. Ian is currently serving as the Vice President of Quality at Tessera Therapeutics, where they are responsible for building the QA and QC units for GxP operations and oversight. Prior to this, Ian worked as the Head of Quality Assurance at Codiak BioSciences, where they built a team of 6 and successfully supported all GXP needs for a Phase 1 company. Ian also played a crucial role in the transformation of Codiak's facility into a GMP-ready site.

Before joining Codiak BioSciences, Ian worked at bluebird bio in various roles, including Director of QA, Head of Global Quality Strategy, and Associate Director of Quality Operations. During their tenure, they oversaw manufacturing and testing operations of contract manufacturers and testing laboratories, improved efficiencies and drove down turnaround times, and successfully transitioned Quality Assurance Operations and Quality Control Operations into one cohesive team.

Ian's earlier experience includes roles at Lonza, Shire, Compliance Implementation Services CIS, and Pfizer (Wyeth Biotech). These positions involved managing quality and compliance, leading teams, conducting investigations, and ensuring regulatory compliance.

Overall, Ian O'Reilly has a strong background in quality assurance and has contributed significantly to the development and improvement of quality systems and processes in the companies they have worked for.

Ian O'Reilly completed their Bachelor of Science degree in Microbial Biotechnology at the Rochester Institute of Technology from 2001 to 2005. Ian continued their education at Southern New Hampshire University, where they earned a Master of Business Administration (MBA) with a focus in Global Studies from 2007 to 2009.

Location

Boston, United States

Links

Previous companies


Org chart


Teams


Offices


Tessera Therapeutics

3 followers

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.


Industries

Employees

11-50

Links